Aberrant DNA methylation occurs early in oncogenesis, is stable, and can be assayed in tissues and body fluids. Therefore, genes with aberrant methylation can provide clues for understanding tumor pathways and are attractive candidates for detection of early neoplastic events. Identification of sequences that optimally discriminate cancer from other diseased and healthy tissues is needed to advance both approaches. Using well-characterized specimens, genome-wide methylation techniques were used to identify candidate markers specific for colorectal neoplasia. To further validate 30 of these candidates from genome-wide analysis and 13 literature-derived genes, including genes involved in cancer and others with unknown functions, a high-throughput methylation-specific oligonucleotide microarray was used. The arrays were probed with bisulfite-converted DNA from 89 colorectal adenocarcinomas, 55 colorectal polyps, 31 inflammatory bowel disease, 115 extracolonic cancers, and 67 healthy tissues. The 20 most discriminating markers were highly methylated in colorectal neoplasia (area under the receiver operating characteristic curve > 0.8; P < 0.0001). Normal epithelium and extracolonic cancers revealed significantly lower methylation. Real-time PCR assays developed for 11 markers were tested on an independent set of 149 samples from colorectal adenocarcinomas, other diseases, and healthy tissues. Microarray results could be reproduced for 10 of 11 marker assays, including eight of the most discriminating markers (area under the receiver operating characteristic curve > 0.72; P < 0.009). The markers with high specificity for colorectal cancer have potential as blood-based screening markers whereas markers that are specific for multiple cancers could potentially be used as prognostic indicators, as biomarkers for therapeutic response monitoring or other diagnostic applications, compelling further investigation into their use in clinical testing and overall roles in tumorigenesis. (Mol Cancer Res 2007;5(2):153 -63) 
Aberrant DNA methylation occurs early in oncogenesis, is stable, and can be assayed in tissues and body fluids. Therefore, genes with aberrant methylation can provide clues for understanding tumor pathways and are attractive candidates for detection of early neoplastic events. Identification of sequences that optimally discriminate cancer from other diseased and healthy tissues is needed to advance both approaches. Using well-characterized specimens, genome-wide methylation techniques were used to identify candidate markers specific for colorectal neoplasia. To further validate 30 of these candidates from genome-wide analysis and 13 literature-derived genes, including genes involved in cancer and others with unknown functions, a high-throughput methylation-specific oligonucleotide microarray was used. The arrays were probed with bisulfite-converted DNA from 89 colorectal adenocarcinomas, 55 colorectal polyps, 31 inflammatory bowel disease, 115 extracolonic cancers, and 67 healthy tissues. The 20 most discriminating markers were highly methylated in colorectal neoplasia (area under the receiver operating characteristic curve > 0.8; P < 0.0001). Normal epithelium and extracolonic cancers revealed significantly lower methylation. Real-time PCR assays developed for 11 markers were tested on an independent set of 149 samples from colorectal adenocarcinomas, other diseases, and healthy tissues. Microarray results could be reproduced for 10 of 11 marker assays,
Introduction
Although colorectal cancer is the second most common cause of malignant death in industrialized countries, the mechanisms and pathways of the neoplastic events associated with this complex disease are not well understood. Genetic alterations in colorectal neoplasia have been studied extensively as candidate markers for detection and analysis of the disease (1) (2) (3) (4) (5) , but much less is known about epigenetic changes, including aberrant methylation of genes. Several genes have been shown to be preferentially hypermethylated in both colorectal cancer and premalignant adenomas with dramatic effects on the expression of their resultant proteins (6) (7) (8) (9) (10) , indicating that silencing of tumor suppressor genes or other genes in tumor pathways can occur both from mutation events and/or aberrant methylation. Application of expression-based microarray profiling has proved effective in distinguishing RNA profile differences between tumor types and classes, providing information for understanding of tumor pathways (11, 12) . Recently, this technology has been adapted to methylation-based microarray profiling, which can distinguish the epigenetic methylation profile of samples from large groups of patients (13, 14) . This type of analysis detects methylation ratios at CpG positions that have been amplified by PCR from bisulfite-modified genomic DNA. By evaluating modified DNA from different patient populations, these arrays have been used to identify methylation markers that distinguish among types of tumors, differentiate tumors from normal tissue, and predict clinical outcome (13) . Because the methylation microarray requires larger amounts of DNA, it is not applicable to clinical situations where only low levels of DNA are available from samples such as biopsies or body fluids. To achieve sensitive detection of DNA methylation from such sources, real-time PCR methods (e.g., MethyLight) can be used to distinguish patient profiles (15) .
From a clinical perspective, more accurate detection markers are needed to improve the effectiveness and efficiency of both the screening and surveillance of colorectal neoplasia. Aberrantly methylated genes represent attractive candidate markers for this purpose because cancer-specific methylation changes occur early in tumorigenesis (16) , seem to be stable, yield a positive amplifiable signal, and can be assayed with high analytic sensitivity. Unfortunately, many or the more commonly described methylation markers in the literature, such as ER, MGMT, MLH1, and CDKN2a, have not been adequately tested for specificity to a target cancer by simultaneously analyzing methylation status across multiple tumor types and normal tissue. As a result, many of these most widely investigated markers are not suitable for specific detection of a particular disease. For example, methylation of the gene CDKN2a (p16) has been reported to be found in blood from patients with numerous types of cancer including oral cancer, gastric cancer, melanoma, nonsmall-cell lung cancer, hepatocellular cancer, and bladder cancer in a number of independent studies (17) (18) (19) (20) (21) (22) . Clearly, methylation of this gene is important in neoplastic progression, but its usefulness as a specific marker for a single cancer in a screening application is questionable. Furthermore, CDKN2a has been shown to be methylated in blood from individuals with noncancerous diseases, albeit at a lower rate (21, 23) .
Because of the genetic heterogeneity of colorectal neoplasia, multiple genetic markers may be required for acceptable tumor detection rates (24, 25) . Because methylation occurs early and in distinct genomic areas, it might be possible to achieve high clinical sensitivity with fewer methylated DNA markers (6) . Feasibility studies have shown that aberrantly methylated DNA markers can be assayed from serum or plasma (16, (26) (27) (28) (29) (30) (31) and from stool (32) (33) (34) to detect colorectal cancer. However, robustly conducted genome-wide searches are needed to identify methylated DNA sequences that optimally discriminate colorectal neoplasia from other tissues and normal blood components.
In this study, we report the use of a genome-wide PCR-based discovery process to identify sequences that are differentially methylated between colorectal neoplasia, normal colon tissue, and peripheral blood lymphocytes (PBL) from healthy agematched individuals. We provide validation of these differential methylation markers via use of both methylation microarrays and real-time PCR for discrimination of colorectal neoplasia compared with healthy mucosa and age-matched healthy PBLs and also with other disease states, including actively inflamed epithelia and malignant tissues. The markers identified are consistent with the concept that hypermethylation is an important proponent of tumorigenesis because several of the candidates found in our genome-wide screening have recently been implicated as being involved in the neoplastic process, and several candidates from our literature-based search that were previously reported to be involved in cancer were verified in this study. The high accuracy of these markers suggests that the sensitive, methylation-specific real-time PCR assays described in this study may be useful for detection of disease at early stages in blood and for interrogation of neoplastic pathways. Based on our comprehensive analysis of these candidate markers in diverse tissue types, we suggest potential applications for the markers.
Results

Genome-Wide Discovery
The discovery process resulted in more than 500 unique sequences that were potential candidates for colorectal cancer biomarkers. The differentially methylated sequences identified by methylation-specific arbitrarily primed PCR (35) and methylated CpG island amplification (36) were scored and prioritized using the following scoring variables: (a) appearance using multiple discovery methods; (b) appearance in multiple pools of like samples; (c) located within a CpG island; (d) located within the promoter region of a gene; (e) located near or within predicted or known genes; (f) known to be associated with disease; (g) class of gene (transcription factor, growth factor, tumor suppressor, oncogene); and (h) repetitive element. Under this scoring schema, a sequence received a point for each of the above criteria and received a score of À8 for having repetitive sequence content >50%. Therefore, the highest score possible was 7; the lowest was À8. Scores were automatically calculated for each sequence using genomic annotations from the Ensembl database. 8 Scoring results for all differentially methylated sequences identified by genome-wide discovery are shown in Supplementary Table S1. Using the scoring criteria above along with manual review of the sequences, 30 sequences were selected for microarray analysis (Table 1) . Sequences with significant (>50%) repetitive element content were eliminated from consideration. Our comprehensive database of sequences derived from internal genome-wide discovery experiments allowed us to also eliminate sequences found using other previously tested tumor types. Selected sequences scored z1, with the majority scoring z3.
Gene Array Study
For additional confirmation of the methylation state of the potential markers, we constructed a methylation-specific gene array containing oligonucleotides representing the 30 selected genome-wide discovery sequences and also 13 potential methylation biomarkers from the literature ( Table 1) . Additional genes were chosen from a previous microarrray study of literature-derived sequences and selected based on involvement in neoplasia and discrimination of colorectal cancer versus pathologically normal colon tissue (data not shown). In our discovery experiments, the exon 1 region of the TMEFF2 gene was identified as being hypermethylated. Because the promoter region of this gene had been described as differentially methylated in the literature (37) and was also shown to discriminate between colorectal cancer and healthy colon in the previous microarray study (data not shown), this region was included as a candidate sequence. TMEFF2 methylation measurements from promoter and exon 1 region are highly correlated (between-amplificate correlation R = 0.76) and were therefore aggregated and treated as one locus for further analysis.
We determined the ability of the 42 differentially methylated gene regions to discriminate between colorectal cancer and other tissues using a large, highly diverse sample set containing colorectal cancer tissue and tissue samples from other types of cancers, colon inflammatory conditions, colon polyps, and numerous histopathologically determined normal tissues.
Hierarchical Clustering
To identify systematic similarities in the overall methylation patterns of samples and genes, we did a hierarchical clustering on the entire gene set and the set of 204 colon-derived tissue DNA samples (Fig. 1) . The majority of normal and inflammatory colon samples fall into a cluster that shows no methylation on most genes (cluster N: 25 normal, 29 inflammatory, 12 colon polyp, and 16 colorectal cancer samples). The other cluster (cluster C) consists predominantly of neoplastic samples and is clearly separated into two subclusters (C1 and C2), which show different degrees of hypermethylation. The subcluster with the strongest methylation is composed only of neoplastic tissue (cluster C1: 28 colon polyp and 38 colorectal cancer samples). The other subcluster shows an intermediate degree of methylation and includes some histologically normal and inflammatory samples (cluster C2: 4 normal, 2 inflammatory, 15 colon polyp, and 35 colorectal cancer samples). There is no significant association between the two neoplastic subclusters and tumor stage or grade. However, there are a significantly higher number of adenomas >1 cm in the subcluster C1 than in the subclusters N and C2 (C1: 14 colon polyps z1 cm, 15 colon polyps <1 cm; C2: 2 colon polyps z1 cm, 13 colon polyps <1 cm; N: 2 colon polyps z1 cm, 11 colon polyps <1 cm; P < 0.01). As can be expected from the directed selection of candidate sequences for the microarray study, the overall clustering results show a clear separation between normal and inflammatory samples in cluster N on the one side and polyp and colorectal cancer samples in cluster C on the other side. Cluster N contains 90% of the nonneoplastic samples. Cluster C contains 81% of the neoplastic and preneoplastic samples. The majority of discriminatory markers are hypermethylated in polyp and colorectal cancer samples from cluster C and show a typical CpG island methylator phenotype (CIMP; ref. 38) . Polyp and colorectal cancer samples in cluster N, on the other hand, are samples not methylated for the majority of discriminatory markers tested and appear to be a CIMPnegative population. The observed strong similarity between the colorectal cancer and colon polyp samples is supported by previous studies that show early alterations in methylation in precancerous conditions of the colon (39, 40) . Based on the clustering results, all subsequent analyses of the data combine the colorectal cancer and colon polyp samples for comparison to normal tissue, other cancers, and inflammatory bowel disease.
Individual Marker Performance
To quantify the influence of non -colon-derived tissues on the classification performance of individual markers, we analyzed the data set in two different ways. First, we looked at the complete sample set. Here, the negative class consisted of 214 samples from normal colon (29) , inflammatory colon (31), PBL (14) , and other normal (10 liver, 7 stomach, and 7 esophagus) and noncolorectal cancer tissues (28 breast cancer, 38 lung cancer, 9 liver cancer, 10 pancreatic cancer, 10 bile duct cancer, 10 stomach cancer, 5 prostate cancer, and 6 esophageal cancer). The positive class was composed of 144 colorectal cancer and polyp samples. Thirty markers were highly significant with P < 0.0001. Ten markers showed a very strong class separation with an area under the receiver operating characteristic curve (AUC) of z0.8 ( Table 2 ). The sensitivity of these strong markers ranged between 35% and 52% at a specificity level of 95%. In a second analysis, we looked only at colon-derived tissues. In this case, the negative class consisted of 60 samples from normal and inflammatory colon. The positive class was again composed of 144 colon cancer and polyp samples. Despite the lower sample number as compared with the full data set, 29 markers were highly significant with P < 0.0001. Nineteen markers showed a very strong class separation with an AUC of z0.8 ( Table 2 ). The sensitivity of these strong markers ranged between 44% and 81% at a specificity level of 95%. The omission of non -colon-derived tissues resulted in a strong increase of DAUC z 0.05 for 17 markers and a strong decrease of DAUC V À0.05 for five markers. Classification results of all individual markers are summarized in Table 2 . 
Marker Panel Performance
Using a panel of markers does not significantly improve performance over the best single marker, TMEFF2. The best two-marker panel is TMEFF2 plus NGFR. This panel has a sensitivity of 55% (confidence interval, 44-68%) at 95% specificity in the classification of all samples (+5% compared with TMEFF2 alone). The sensitivity in classifying only colon-derived tissue samples is 85% (confidence interval, 75-93%) at 95% specificity (+4% compared with TMEFF2 alone).
Paneling does not significantly increase sensitivity of the markers for colorectal cancer over TMEFF2 alone because all of our markers detect the same subset of colorectal cancer and polyp samples. The CIMP-positive cancer cluster shown in Fig. 2 (cluster C) includes 81% of the colorectal cancer and polyp samples in the study. TMEFF2 alone is heavily hypermethylated on 67% of these CIMP-positive samples (78 of 116 CIMP samples with TMEFF2 methylation >10%). Only 11% of the remaining CIMP-negative colorectal cancer and polyp samples show TMEFF2 hypermethylation (3 of 28 CIMP-negative samples with TMEFF2 methylation >10%). Because no additional marker shows significant hypermethylation on the CIMP-negative samples or significantly higher methylation levels than TMEFF2 on the CIMP-positive samples, overall marker complementarity is minimal.
Distribution of Methylation Frequencies
To further understand the behavior of the strongest markers on different tissue types, we looked at the distribution of methylation frequencies on all 358 samples grouped into five major tissue classes. For this analysis, colorectal cancer and polyp samples, as well as normal and inflammatory colon tissue samples, were combined because their respective methylation rate distributions were similar. Figure 2 shows box plots of the major tissue classes for all markers from the gene array with an AUC of z0.8. Median methylation levels of all tissue subclasses are shown in Fig. 3 and detailed box plots for all tissue subclasses can be found in Supplementary Fig. S1 . The overall low degree of methylation of markers GSK3B, RNF4, and CD44 is a result of the poor correlation between different CpG positions within the same amplicon (median between CpG correlations: GSK3B, R = 0.27; RNF4, R = 0.28; CD44, R = 0.41; all other 17 most discriminating markers, R z 0.47) and indicates a lack of comethylation within the CpG island.
Generally, all markers, with the exception of APC, show hypermethylation of the colorectal cancer class compared with the healthy colon and the PBL class. However, the methylation patterns of our markers differ considerably with regard to the noncolonic healthy tissues and noncolonic cancer classes. Markers TMEFF2, ZDHHC22, SLITRK1, SLC32A1, DLX5, GSK3B, NGFR, PCDH17, N33, and BCOR differentiate colon neoplasia very well from the majority of other tissues (AUC z 0.8). All show strong hypermethylation of colorectal cancer compared with other tissues with varying differences among the other tissue classes. Other markers such as RNF4, SIX6, CD44, CSPG2, CDH13, GPR7, EYA4, ALX4, and APC show only small or no differences between colorectal cancer and the noncolonic cancer class. N33 not only shows significant hypermethylation of colorectal cancer compared with normal colon but also gives a very strong discrimination between colon tissue (normal colon and colorectal cancer) and most other tissues. All of our markers show some degree of hypermethylation in stomach and esophageal cancer tissue and, to some lower extent, in normal stomach tissue.
Marker Validation with MethyLight Assays
We developed 11 real-time MethyLight assays for markers that were designated as having strong to poor performance on the gene array. Nine of the markers had very high performance (AUC z 0.8) in the colon tissue only classification (TMEFF2, ZDHHC21, SLITRK1, SSLC32A, NGFR, N33, RNF4, EYA4, and ALX4). Two markers with poorer performance (BCL6 and SMAD7) were tested because, although the array results were not strong, original discovery scoring of these sequences was high (6 and 4, respectively), and this information would also allow us to further correlate array performance results with realtime assay results. For TMEFF2, the real-time assay was designed in the promoter region of the gene. Classification performance of the MethyLight assays was estimated on an independent sample set with a negative class of normal and normal adjacent colon (46 samples), inflammatory colon (9 samples), and other cancerous tissues (15 breast cancer and 15 liver cancer). The positive class was composed of 39 colon cancer and adenoma samples. Of the nine MethyLight assays for the strongest gene array markers, five (TMEFF2, ZDHHC21, NGFR, N33, and EYA4) were highly significant (P < 0.0001) and showed a substantial class separation with an AUC of z0.8 ( Table 2 ). Three assays (SLITRK1, SSLC32A, and ALX4) showed a significant but weaker class separation (P < 0.009; AUC > 0.72). RNF4, a strong candidate from the gene array, could not be reproduced using real-time PCR analysis because almost all amplifications yielded no product. This is likely due to a lack of significant comethylation of CpG sites within the assay region but was not further investigated. The two poorer performing gene array markers (BCL6 and SMAD7) showed poor results with their corresponding realtime MethyLight assays, confirming results obtained with the gene array. The sensitivity of the five strongest markers ranged between 55% and 83% at a specificity level of 95%. Figure 2 shows the methylation frequency distributions of the nine MethyLight assays for the most discriminative gene array markers. The scale of methylation level for these real-time assays is extended to 0.01% methylation as compared with 1% methylation used for the gene array data because of the increased sensitivity of real-time PCR. At this level of analytic sensitivity, TMEFF2, ZDHHC22, and NGFR are completely negative on PBL and show high specificity with regard to other tissues, indicating that these markers may be excellent candidates for blood-based early detection applications. TMEFF2, ZDHHC22, and EYA4 all have minimal overlap of methylation levels between colorectal cancer and normal and inflammatory colon tissue, making them potential candidates for stool-based assays or molecular classification tests; however, quantitation would be necessary for these analyses.
Discussion
Using the combined approach of genome-wide methylation discovery with candidate marker identification, followed by microarray analysis and real-time PCR verification, we identified a set of highly methylated sequences that are present in colorectal neoplasia. We identified markers such as TMEFF2, NGFR, and ZDHHC22 that have high specificity in the diverse sample set and may be useful in clinical applications, such as noninvasive screening for detection of colorectal neoplasia in either blood-or stool-based tests. We also found markers that discriminate between normal colon and tissue with early neoplastic changes, which have potential for use in molecular classification of colon tissue to more accurately determine early neoplastic changes, tumor aggressiveness, or treatment response. For example, TMEFF2, ZDHHC22, and EYA4 could be useful for molecular classification of early stages of disease in applications such as inflammatory bowel disease surveillance.
Many genes identified during our discovery and validation process have not been reported to be methylated in the setting of cancer biology and may provide insight into gene regulation. BCOR has been shown to be associated with genes involved in cancer or regulation of cell growth. Recent studies indicate that BCOR is a transcriptional repressor of BCL6, a proto-oncogene, and is an important transcriptional regulator of embryogenesis (41, 42) . Inactivation of this gene by methylation in the promoter region could provide a selective advantage for malignant cell growth. NGFR, also known as p75 (NTR), was recently identified as a tumor suppressor gene that induces apoptosis in malignant cells (43) . No association with methylation in the promoter region of this gene or inhibition of this gene by methylation has previously been described. Other identified genes such as SLITRK1 and SLC32A1 have neither been associated with cancer nor reported as having aberrant methylation in their promoter regions. Interestingly, another solute carrier family member, SLC5A8, has been implicated as a tumor suppressor and was shown to be methylated in both gastric cancer cell lines and primary gastric cancers (44) . Clearly, these genes warrant further investigation into their roles in malignant transformation.
Because >90% of the marker candidates identified in the methylation array study could be validated by real-time PCR (MethyLight) analysis, these data support the use of our process to identify and confirm methylation biomarkers. By using a broad genome-wide method to identify initial candidates along with a systematic selection system to differentiate those candidates with characteristics most likely to be biologically important, followed by verification on methylation microarrays and finally validation by real-time PCR, we have clearly shown that valuable biomarkers for oncological diagnostic applications, such as TMEFF2, ZDHHC22, and NGFR, can be found.
It is also evident that the markers identified in this study do not identify all colorectal cancer tissues. The lack of increase in sensitivity with paneling of the markers and the inability to identify all colorectal tumors with these panels are thought to be due to the manner in which our markers were identified and also potentially due to biology. Because, at all stages in our process, we identified and tested our markers in relation to healthy samples and other cancers, we have eliminated many markers that are methylated to any degree in these tissues. For example, GSK3B, EYA4, and APC were not identified in our discovery process and, although very highly methylated in colorectal cancer and adenomas, they are also methylated in other cancers and healthy tissues. Due to the use of pooling in our initial genome-wide discovery experiments, we also introduced a bias towards markers that show hypermethylation in a majority of colorectal cancer samples. The signal of a hypothetical marker having hypermethylation only on a small subclass of colorectal cancer samples would have been effectively diluted out by the pooling procedure. However, biologically, one can question whether methylation changes occur in all colorectal tumors. Indeed, we observed that many of the tumors with increased methylation in one marker exhibit increased methylation in multiple regions, as also reported by Issa (45) . Are the remaining samples a CIMP-negative population? Follow-on marker identification studies will therefore be focused on studying the tissues that are methylation negative for the current marker set to answer this question.
In addition, further analysis of these candidate marker genes with close attention to their association with clinical variables, such as age, sex, colonic location, smoking history, family history, and others, which have been shown to be key predictors of cancer phenotype and clinical outcomes, could provide additional insight into their potential as biomarkers. Further prospective studies of these markers, based on real-time PCR assays, either in a remote sample amenable to population screening or in biopsy samples from longitudinal studies, are indicated.
Materials and Methods
Patient Samples
Institutional review boards at all participating sites approved this study. A complete list of all patient samples used in this study is found in Supplementary Table S2 .
Genome-Wide Discovery. Differentially methylated sequences were identified using pathologically verified colonic tissue samples obtained from the National Disease Research Interchange (Philadelphia, PA), the Cooperative Human Tissue Network (Nashville, TN), and ILSbio (Chestertown, MD). These included 25 adenocarcinomas, 6 adenomas, and 42 tumor-free control tissues. Normal blood for peripheral blood lymphocyte isolation was obtained from Puget Sound Blood Center (Seattle, WA).
Gene Array. Pathologically verified tissues were obtained from surgical procedures or endoscopic biopsies done at the Mayo Clinic (Rochester, MN), Semmelweis University Clinic (Budapest, Hungary), or University Hospital Carl Gustav Carus (Dresden, Germany). All normal tissues were obtained from patients endoscopically verified as absent of lesions and without a history of neoplasia. The total sample set included 358 patient DNAs and 2 control DNAs. The patient DNAs were extracted from 29 normal colon samples; 31 inflammatory bowel disease; 55 colon polyps (45 polyps <1 cm, 10 polyps z1 cm); 89 colorectal cancers (30 Dukes A/B, 56 Dukes C/D, 1 unknown, 2 high-grade polyps z1 cm); 116 noncolonic cancer samples from liver (9), bile duct (10), pancreas (10), lung (squamous and adenocarcinoma; 38), breast (28) , prostate (5), esophagus (6), stomach (10) , and normal tissue from sites other than colon: PBL (14) , esophagus mucosa (7), gastric mucosa (7), and liver (10) .
Additionally, one control sample of unmethylated human DNA (Molecular Staging, New Haven, CT) and one control sample of enzymatically methylated DNA (SssI; New England Biomedical) were included. All colon and lung tissues were matched by age/sex as well as location in the colon and the lung (central and peripheral).
MethyLight Assays. Pathologically verified tissues were obtained from surgical procedures or endoscopic biopsies done at the Mayo Clinic (Rochester, MN), Semmelweis University Clinic (Budapest, Hungary), or University Hospital Carl Gustav Carus (Dresden, Germany), or by commercial sample collections done by Asterand (Detroit, MI), Integrated Lab Services (Research Triangle Park, NC), and Clinomics (Pittsfield, MA) in accordance with a provided specimen collection protocol. The total sample set included 149 patient DNAs from normal colon tissue (18) , pathologically normal colon tissue adjacent to tumor (28) , normal PBLs (25), inflammatory bowel disease (9), colon polyps (11), colorectal cancers (28), breast cancer (15) , and liver cancer (15) . Not all assays were run on all samples because of limited DNA amounts.
DNA Extraction
DNA extraction of snap-frozen surgical samples for discovery was done using Genomic Tip-500 columns (Qiagen, Valencia, CA). Extraction for the microarray and real-time PCR assays was optimized by sample type including tissue sections from snap-frozen tissue, frozen surgical specimens, and snapfrozen small biopsies. Surgical specimens from University Hospital Carl Gustav Carus were extracted using Genomic Tip-100 columns. Frozen tissue sections from Mayo Clinic were extracted using a MagNa Pure device (Roche Applied Science, Indianapolis, IN). DNA from biopsies done at Semmelweis University Clinic was prepared using Qiagen buffers and the High Pure PCR Template Preparation Kit (Roche Applied Science).
Genome-Wide Identification of Differentially Methylated Sequences
To identify markers with high specificity for colon cancer, we used pooled genomic DNA from colonic normal, adenoma, and adenocarcinoma tissues and analyzed them using the previously described methods, methylation-specific arbitrarily primed PCR (35) and methylated CpG island amplification (36) .
Patient samples used in these experiments were divided into three age groups: >65, 50 to 65, and <50 years. Samples were also divided into four types depending on the extent of disease: (a) normal adjacent tissue (>6 cm from tumor) or no disease, (b) adenomas, (c) cancer with no nodal involvement or metastasis (N 0 M 0 ), and (d) advanced disease with nodal involvement (N 1-2 M 0 ) and/or metastasis (N 1-2 M 1 ). For each of these age and disease groups, three to five patient samples were combined into one pool. In addition, methylation patterns of all cancerous and precancerous conditions from all age groups were compared with age-matched normal peripheral blood lymphocytes.
Gene Array
The microarray was done as previously specified (13) with oligonucleotides covering regions of 43 discovery experimentand literature-derived genes and 2 control genes. For the discovery experiment -derived genes, primer pairs and oligonucleotides were designed around the identified differentially methylated sequence whenever possible. Multiple primer pairs and oligonucleotides were designed for some genes for a total of 54 amplicons and a total of 248 oligonucleotide pairs. Each oligonucleotide contained two to three CpG sites. Hybridization conditions allowed the detection of single nucleotide differences. Additionally, eight negative control oligonucleotides with random sequences were included to facilitate estimation of unspecific background hybridization. The methylation proportion of each oligonucleotide was estimated from four spot repetitions per microarray and, on average, four hybridization repetitions per sample using a maximum likelihood algorithm. 9 Unmethylated human DNA (Molecular Staging) and enzymatically methylated control DNAs (SssI; New England Biomedical) were used to calibrate the data. Amplicons for all discovery genes, candidate genes, and control genes used in the combined array are shown in Supplementary Table S3 .
MethyLight Assays
The MethyLight assays were done on the ABI Prism 7900 (Applied Biosystems) using standard TaqMan chemistry as previously reported by Eads et al. (15) .
Standard curves for each assay were established using CpGenome Universal Methylated DNA (Millipore/Chemicon, Temecula, CA) at concentrations between 31.6 pg/AL and 31.6 ng/AL DNA. Sample DNA was diluted to 2 ng/AL and aliquoted into strip tubes for three assays. Ten nanograms of DNA per reaction were tested in duplicate for each assay. A methylation-unspecific assay for h-actin was used to determine total bisulfite-treated DNA concentration for each sample. Assay components and running conditions are shown in Supplementary Table S4 .
Statistical Analysis
Analysis of the gene array was done on log 10 -transformed methylation proportions averaged over all CpG positions from the same gene by computing the mean.
Hierarchical clustering of the gene array data was done by using the simple two-norm as distance metric between samples and between genes. Samples and genes were clustered using Ward's minimum variance method (46 AUC values were estimated using the trapezoidal rule. P values were computed with a Wilcoxon test. A simple cutoff classifier was used for classification. Sensitivity and specificity were estimated by 200 bootstrapping runs that randomly divided the data set into training set (about two thirds of the samples) and test set (about one third of the samples). For every bootstrap run, the cutoff was set to 95% specificity on the respective training set. Sensitivity and specificity were then computed from the respective test set. We report median sensitivity and specificity values from the 200 bootstrap runs as well as 90% confidence intervals (5% and 95% quantiles of the bootstrap estimates). For the two-marker panel analysis, the reported panel value for each sample was computed by taking the maximum of the two individual marker measurement values.
MethyLight analysis was done on the ratio of methylated DNA (measured by the respective marker assay) to total bisulfite DNA (measured by the h-actin assay). Ideally, this ratio results in a number in the range [0, 1] and represents the proportion of methylated DNA in the respective sample. DNA amounts were estimated from the respective standard curves by linear regression. Replicate marker measurements were averaged.
